Research programme: anti-COVID-2019 monoclonal antibodies - Twist Bioscience
Alternative Names: anti-ACE2 antibody - Twist BioscienceLatest Information Update: 28 Oct 2024
At a glance
- Originator Twist Bioscience
- Developer Saint Louis University; Twist Bioscience
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (Parenteral)
- 02 Sep 2020 Preclinical trials in COVID-2019 infections in USA (Parenteral) before September 2020
- 02 Sep 2020 Interim pharmacodynamics data from research phase trial in COVID-19 infections released by Twist Bioscience